These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. [Theoretical and experimental substantiation of immunosorption procedures]. Pokrovskiĭ SN; Adamova IIu; Babiĭ AV Kardiologiia; 1986 Oct; 26(10):49-54. PubMed ID: 3795703 [TBL] [Abstract][Full Text] [Related]
31. Therapeutic efficiency of lipoprotein(a) reduction by low-density lipoprotein immunoapheresis. Banyai S; Streicher J; Strobl W; Gabriel H; Gottsauner-Wolf M; Rohac M; Weidinger F; Hörl WH; Derfler K Metabolism; 1998 Sep; 47(9):1058-64. PubMed ID: 9751233 [TBL] [Abstract][Full Text] [Related]
32. Effect of low-density lipoprotein apheresis on kinetics of apolipoprotein B in heterozygous familial hypercholesterolemia. Maugeais C; Ouguerram K; Frénais R; Maugère P; Charbonnel B; Magot T; Krempf M J Clin Endocrinol Metab; 2001 Apr; 86(4):1679-86. PubMed ID: 11297603 [TBL] [Abstract][Full Text] [Related]
33. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Aengevaeren WR; Kroon AA; Stalenhoef AF; Uijen GJ; van der Werf T J Am Coll Cardiol; 1996 Dec; 28(7):1696-704. PubMed ID: 8962554 [TBL] [Abstract][Full Text] [Related]
34. [Biological efficacy of LDL apheresis in major hypercholesterolemia]. Dairou F; Assogba U; Bruckert E; De Gennes JL; Turpin G Ann Med Interne (Paris); 1994; 145(5):328-32. PubMed ID: 7985942 [TBL] [Abstract][Full Text] [Related]
35. Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments. Lane DM; Alaupovic P; Knight-Gibson C; Dudley VS; Laughlin LO Am J Cardiol; 1995 Jun; 75(16):1124-9. PubMed ID: 7762498 [TBL] [Abstract][Full Text] [Related]
36. Low density lipoprotein hemoperfusion by direct adsorption of lipoproteins from whole blood (DALI apheresis): clinical experience from a single center. Bosch T; Lennertz A; Kordes B; Samtleben W Ther Apher; 1999 Aug; 3(3):209-13. PubMed ID: 10427617 [TBL] [Abstract][Full Text] [Related]
37. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320 [TBL] [Abstract][Full Text] [Related]
38. Long-term effect of low-density lipoprotein apheresis in a patient with heterozygous familial hypercholesterolemia: follow-up study using coronary angiography. Saku K; Takeda Y; Jimi S; Okabe M; Shirai K; Nii T; Naito S; Arakawa K J Cardiol; 1998 Apr; 31(4):239-45. PubMed ID: 9594373 [TBL] [Abstract][Full Text] [Related]
39. LDL hemoperfusion--a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients. Bosch T; Schmidt B; Kleophas W; Otto V; Samtleben W Artif Organs; 1997 Oct; 21(10):1060-5. PubMed ID: 9335362 [TBL] [Abstract][Full Text] [Related]
40. The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. Rasouli M; Kiasari AM; Mokhberi V Clin Chem Lab Med; 2006; 44(8):1015-21. PubMed ID: 16879071 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]